Differentiating the efficacy of the tumor necrosis factor inhibitors.
about
Tumor necrosis factor-alpha inhibitor treatment for sarcoidosisEtanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss.Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy.Dramatic response to infliximab in refractory neurosarcoidosis.Treatment of sarcoid granulomatous interstitial nephritis with adalimumab.Growth retardation and delayed puberty in children and adolescents with juvenile idiopathic arthritis.Adalimumab in the therapy of uveitis in childhoodOpen-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study.Immunosuppression related to collagen-vascular disease or its treatment.Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis.Adalimumab induced pulmonary sarcoid reaction.Clinically validated approaches to the treatment of autoimmune diseases.Infliximab for peripheral ulcerative keratitis treatment.Adalimumab in the treatment of arthritisDevelopment of myeloperoxidase-antineutrophil cytoplasmic antibody-associated renal vasculitis in a patient receiving treatment with anti-tumor necrosis factor-α.Effect of tumor necrosis factor-α antagonism in asthma: a meta-analysis of the published literature.Correlation of protease-activated receptor-2 expression and synovitis in rheumatoid and osteoarthritis.Pulmonary sarcoidosis associated with etanercept therapy.[A case of recurrent breast cancer with life-threatening multiple lung metastasis markedly responding to CMF as third-line chemotherapy].
P2860
Q24652971-26F4C292-2CF1-4DF3-957D-66C19D03A51CQ30009390-01D36566-A736-4813-B6A5-1ADA43050585Q33401933-2320CD4D-99B8-44CA-9684-E03F1D31F442Q34312001-5D84D1C5-B626-4192-87F7-F3E5EE5E84FCQ35573936-8D7AA1A8-6F2F-4CD6-9D11-560F55433F78Q35755313-69367560-43DE-47F4-8118-652D989C3A5AQ35763157-5109F383-9A43-4B2A-AEF0-974D49CFEA56Q35954453-A1CD1D84-4A85-4CAF-9A19-3FC6A9B64712Q36328708-91769F59-C914-420D-9905-5C5FCAAEC723Q36847326-2A23D8DC-9404-45F4-B75F-5AF5F18F75B4Q37576496-F596D98F-0E30-4606-8290-958D04D6871BQ37668612-DC0C129F-9DAB-45B1-B34D-EB7755A4AC9AQ38283034-B12143D2-5A0C-4B82-80BC-1A99BEDA29A4Q42009131-D9D22924-D36D-4078-A093-614F2C488315Q42948710-532A6EE2-5D39-478D-8E84-4400A67CB3E9Q44202329-AC142110-F284-4AE6-B8C4-87BE5BCC8EF9Q44432812-607C314C-2432-40D6-88B1-8124C3534220Q46981061-71A56E80-550E-4296-8551-3A6A0540E196Q46986955-F60F1434-F587-4F5A-AA12-E26C2E39D3DE
P2860
Differentiating the efficacy of the tumor necrosis factor inhibitors.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Differentiating the efficacy of the tumor necrosis factor inhibitors.
@ast
Differentiating the efficacy of the tumor necrosis factor inhibitors.
@en
type
label
Differentiating the efficacy of the tumor necrosis factor inhibitors.
@ast
Differentiating the efficacy of the tumor necrosis factor inhibitors.
@en
prefLabel
Differentiating the efficacy of the tumor necrosis factor inhibitors.
@ast
Differentiating the efficacy of the tumor necrosis factor inhibitors.
@en
P1476
Differentiating the efficacy of the tumor necrosis factor inhibitors.
@en
P2093
Boulos Haraoui
P356
10.1016/J.SEMARTHRIT.2005.01.003
P433
P577
2005-04-01T00:00:00Z